Eterna Therapeutics, Inc. (ERNA) announced Tuesday positive results from a preclinical study on the company's lead cell therapy ...

Cells is under clinical development by ICamuno Biotherapeutics and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase I drugs for Ovarian Cancer have a 73% phase transition ...

By successfully turning the “cold” tumor into “hot” – transforming the tumor microenvironment from having low immune activity to an active immune environment – ERNA-101 may not only lead to improved ...

June 23, 2023 — Using 3-D models of ovarian cancer tumors, scientists found differences in gene activity based on where a cell is in a tumor, demonstrating how a cell's location and environment ...

When the labeled antibody was released near ovarian cancer cells, its Y-shaped arms bound to the cells. The researchers then fused the labeled arms to the stem of a human antibody, generating a ...

Retraction Note: Genistein inhibits stemness of SKOV3 cells induced by macrophages co-cultured with ovarian cancer stem-like cells through IL-8/STAT3 axis. Retraction Note: Hsa_circ_0001944 ...

Despite recent therapeutic breakthroughs, cancer patients continue to face high recurrence and mortality rates due to treatment resistance. Cancer stem cells (CSCs), a subpopulation with self-renewal ...

“We aim to extend our study to decipher the collective dynamics of such cancer cells, especially in more complex 3D environments. This will shed fresh light on the pathology of ovarian ...